Michael Gold

Anaphylaxis: Revision of the Brighton collaboration case definition

Effects of an Amino Acid-Based Formula Supplemented with Two Human Milk Oligosaccharides on Growth, Tolerability, Safety, and Gut Microbiome in Infants with Cow’s Milk Protein Allergy

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Current directions in tau research: Highlights from Tau 2020

Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates

Efficacy of m-Health for the detection of adverse events following immunization – The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial

Consumer acceptability and validity of m-Health for the detection of adverse events following immunization – The Stimulated Telephone Assisted Rapid Safety Surveillance (STARSS) randomised control trial

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

Association Between the Implementation of a Population-Based Primary Care Payment System and Achievement on Quality Measures in Hawaii

Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials

CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP

International Consensus (ICON): allergic reactions to vaccines

Progression of brain atrophy in PSP and CBS over 6 months and 1 year

Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases

Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development

The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)